Sublingual Immunotherapy Side Effects: The Clinical Adverse-Event Profile

Local side effects occur at or near the site of contact in the mouth and include itching under the tongue, throat irritation, ear itching, and minor lip or tongue swelling. They reflect local immune engagement with the allergen and are by far the most common adverse-event category, affecting roughly 40.8 percent of patients in the 2024 Janz meta-analysis. Systemic side effects involve the body beyond the mouth, such as widespread hives, wheezing, or lightheadedness, and indicate a broader immune response. These are far less frequent, affecting fewer than 0.1 percent of patients in our program, and are predominantly mild. The practical distinction matters: local reactions are generally expected and self-limiting, while systemic reactions warrant contacting your provider and, if severe, emergency care. Knowing which category a symptom falls into helps you respond appropriately.

The FDA-approved SLIT tablets generated structured adverse-event tables in their registration trials, which is useful clinical context even though the tablets differ from compounded liquid drops. Across the grass tablets (Grastek, Oralair), the ragweed tablet (Ragwitek), and the house dust mite tablet (Odactra), the most frequently reported treatment-related events were local application-site reactions: oral pruritus, throat irritation, mouth edema, ear pruritus, and tongue swelling, typically affecting a substantial minority to a majority of treated subjects and generally mild to moderate in the early weeks. Systemic reactions were infrequent. These tablet trial tables are distinct from the compounded multi-allergen liquid drops, which are not FDA-approved and rely on the broader, largely European meta-analytic evidence such as Janz 2024 (about 40.8 percent local); systemic reactions are far less common, affecting fewer than 0.1 percent of patients in our program. The categories align closely; the regulatory pathway and exact percentages do not transfer directly.

Systemic reactions to sublingual immunotherapy are uncommon and most are mild, but a small number can be more serious, which is why they deserve attention. Symptoms such as widespread hives, wheezing, throat swelling, or faintness signal that the reaction has moved beyond the mouth and require prompt medical contact. The most severe form, anaphylaxis, is exceptionally rare in SLIT, estimated near 1 per 100 million doses, and no SLIT fatality has been reported worldwide. Because severe reactions are possible in theory, providers commonly supervise the first dose and may prescribe an epinephrine auto-injector as a precaution. The overall picture is reassuring: the evidence suggests SLIT carries a lower risk of systemic reactions than injected immunotherapy. Still, anyone experiencing a systemic reaction should stop dosing and seek evaluation rather than continuing on their own.

Certain conditions are contraindications to sublingual immunotherapy. Uncontrolled or severe asthma is one of the most important, because poorly controlled airways increase the risk if a systemic reaction occurs, so asthma should be well controlled before starting. Eosinophilic esophagitis is another contraindication, since the sublingual and swallowed allergen route has been associated with this condition. People with certain other medical circumstances, such as some cardiovascular conditions or specific medication regimens, may also need individualized review before starting. A provider evaluates your full medical history, current medications, and the degree of asthma control before recommending treatment. This pre-treatment screen is a routine part of starting immunotherapy and helps ensure the approach is appropriate for you. If you have any of these conditions, discuss them openly with your provider so the plan can be tailored or an alternative considered.

Liquid sublingual drops and FDA-approved sublingual tablets share the same fundamental route, allergen contact with the oral mucosa, so their side-effect categories are broadly similar, dominated by local oral and throat reactions. Some evidence suggests drops may produce slightly milder local irritation because concentration per unit can be lower, while tablets dissolve rapidly and deliver a more concentrated bolus, though differences where observed are modest. The more meaningful distinction is regulatory: tablets such as Grastek, Ragwitek, and Odactra completed FDA approval, while custom multi-allergen liquid drops are compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy, so they rely on the broader and largely European evidence base. Both share the favorable systemic safety picture, with no SLIT fatality reported worldwide for either formulation. Your provider can explain which option fits your triggers.